ETRM Share Price

Open 0.08 Change Price %
High 0.08 1 Day 0.00 0.00
Low 0.06 1 Week 0.02 40.00
Close 0.07 1 Month 0.00 0.00
Volume 36901827 1 Year -0.10 -58.82
52 Week High 1.89
52 Week Low 0.04
ETRM Important Levels
Resistance 2 0.09
Resistance 1 0.08
Pivot 0.07
Support 1 0.06
Support 2 0.05
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

EnteroMedics Inc. (NASDAQ: ETRM)

ETRM Technical Analysis 5
As on 9th Dec 2016 ETRM Share Price closed @ 0.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.52 & Strong Sell for SHORT-TERM with Stoploss of 0.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
ETRM Target for December
1st Target up-side 0.09
2nd Target up-side 0.11
3rd Target up-side 0.14
1st Target down-side 0.01
2nd Target down-side -0.01
3rd Target down-side -0.04
ETRM Other Details
Segment EQ
Market Capital 103181296.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.enteromedics.com
ETRM Address
ETRM
2800 Patton Road
St. Paul, MN 55113
United States
Phone: 651-634-3003
Fax: 651-634-3212
Interactive Technical Analysis Chart EnteroMedics Inc. ( ETRM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on EnteroMedics Inc.
ETRM Business Profile
EnteroMedics Inc. (EnteroMedics) is a development- stage medical device company. The Company focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company�s neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company�s initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. As of December 31, 2011, the Company�s enrollment and implantation in randomized, double-blind, parallel-group, multicenter pivotal clinical trial (the ReCharge trial), was completed in 233 patients at 10 centers.